Conclusion: ACSM6 has the potential to serve as a valuable predictor of the tumor microenvironment phenotypes and treatment outcomes in BLCA, thereby contributing to more precise treatment. The gene discussed is ACSM6; the disease is bladder transitional cell carcinoma.